Completeness of reporting of basal cell carcinoma and squamous cell carcinoma to a pharmacovigilance register and the Health and Social Care Information Centre.

Document Version
Final published version

Link to publication record in Manchester Research Explorer

Citation for published version (APA):

Citing this paper
Please note that where the full-text provided on Manchester Research Explorer is the Author Accepted Manuscript or Proof version this may differ from the final Published version. If citing, it is advised that you check and use the publisher’s definitive version.

General rights
Copyright and moral rights for the publications made accessible in the Research Explorer are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

Takedown policy
If you believe that this document breaches copyright please refer to the University of Manchester's Takedown Procedures [http://man.ac.uk/04Y6Bo] or contact uml.scholarlycommunications@manchester.ac.uk providing relevant details, so we can investigate your claim.

Download date: 10. Sep. 2020
Completeness of reporting of basal cell carcinoma and squamous cell carcinoma to a pharmacovigilance register and the Health and Social Care Information Centre.


1. Division of Musculoskeletal and Dermatological Sciences, The University of Manchester, Manchester, United Kingdom;
2. Institute of Cellular Medicine, Newcastle University, Newcastle, United Kingdom;
3. Division of Pharmacy and Optometry, The University of Manchester, Manchester, United Kingdom;
4. Department of Dermatology, Western Infirmary, Glasgow, United Kingdom;
5. Division of Applied Medicine, University of Aberdeen, Aberdeen, United Kingdom;
6. St John’s Institute of Dermatology, King’s College London, London, United Kingdom;
7. Population and Cancer Studies Unit, Queensland Institute of Medical Research, Brisbane, Australia.

BACKGROUND
- The British Association of Dermatologists Biologic Interventions Register (BADBIR) is a prospective, observational, web-based pharmacovigilance register of psoriasis patients recruited from 153 dermatology centres in the UK and Republic of Ireland.
- Data are uploaded by clinical teams to the BADBIR database.
- The aim of the registry is to explore the long-term safety of biologic agents compared to conventional systemic agents.
- Patients are flagged using their NHS number with the Health and Social Care Information Centre (HSCIC), which collates the death and malignancy data for England and Wales.
- The completeness of reporting of basal cell carcinoma (BCC) and cutaneous squamous cell carcinoma (SCC) in each register is unknown.

OBJECTIVE
To investigate the overlap of reporting of BCC and SCC to BADBIR and the HSCIC.

METHODS
Figure 1: BADBIR study design

Inclusion: registration before 01/12/2014; patients in England and Wales only;
Exclusion: in situ SCCs (Bowen’s disease);
Outcomes: previous BCCs and SCCs (before BADBIR registration); incident BCCs and SCCs (after BADBIR registration);
Matching: by type; incident BCC and SCC within 1 month.

RESULTS
- 142 incident cancers for 86 patients were recorded with BADBIR; 32 incident cancers for 29 patients were recorded with HSCIC (Table 1; Figure 2A).
- In total, 152 incident cancers were recorded for 94 patients.
- 318 previous cancers for 150 patients were recorded with BADBIR; 105 previous cancers for 86 patients were recorded with HSCIC (Table 1; Figure 2B).
- In total, 344 previous cancers were recorded for 172 patients.

Table 1: Number of patients and cancers reported to each registry: n patients (n cancers)

<table>
<thead>
<tr>
<th>Registry</th>
<th>BCC (n)</th>
<th>SCC (n)</th>
<th>Total (n)</th>
<th>BCC</th>
<th>SCC</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>BADBIR</td>
<td>53 (79)</td>
<td>39 (63)</td>
<td>86 (142)</td>
<td>113 (177)</td>
<td>54 (141)</td>
<td>150 (316)</td>
</tr>
<tr>
<td>HSCIC</td>
<td>15 (15)</td>
<td>16 (17)</td>
<td>32 (32)</td>
<td>69 (69)</td>
<td>34 (36)</td>
<td>94 (105)</td>
</tr>
<tr>
<td>Total</td>
<td>57 (83)</td>
<td>45 (69)</td>
<td>94 (152)</td>
<td>130 (194)</td>
<td>62 (150)</td>
<td>172 (344)</td>
</tr>
</tbody>
</table>

Figure 2: Overlap in incident (A) and previous (B) cancers reported to BADBIR and HSCIC

- 91 patients were recorded in both databases, but only 22 of 68 SAEs and 79 of 204 previous cancers were matched for these patients.

CONCLUSION
- The findings suggest that the reporting of SCCs and BCCs is more complete in BADBIR than in HSCIC.
- Since undertaking this piece of work, it was identified that HSCIC in England record the first SCC and/or BCC per patient1; this accounts for a substantial proportion of BCCs and SCCs missed by HSCIC, but not for the discrepancy in patients with a cancer.
- Failure to use linked sources may lead to biased estimates of the incidence of SCCs and BCCs.

REFERENCES

ACKNOWLEDGEMENTS
The authors express their gratitude to all patients, centres, the BADBIR team, BAD, sponsors, and all current and/or former members of the BADBIR steering committee.

Disclosures
BADBIR is coordinated by the University of Manchester. BADBIR is funded by the British Association of Dermatologists (BAD). The BAD receives income from AbbVie, Janssen Cilag, Novartis, Samsung Bioepis and Pfizer for providing pharmacovigilance services. This income finances a separate contract between the BAD and the University of Manchester who coordinate BADBIR. All decisions concerning analysis, interpretation, and publication are made independently of any industrial contribution.

KJM received lecture fees from Janssen Cilag (Dec. 2015).